Opinion|Videos|September 3, 2024
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some common adverse events that you’ve seen in your clinical practice associated with BCMA-directed therapies?
- What mitigation strategies are you implementing to alleviate adverse events?
Advertisement
Related to this article
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Trastuzumab Botidotin Prolongs PFS vs T-DM1 in HER2+ Advanced Breast Cancer
2
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
3
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
4
How Does Azacitidine/Venetoclax Impact Hospital Burden in AML?
5